Anika Therapeutics, Inc. (ANIK) vs EyePoint Pharmaceuticals, Inc. (EYPT)
A side-by-side comparison of Anika Therapeutics, Inc. and EyePoint Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANIK
Anika Therapeutics, Inc.
$19.57HealthcareDelayed quote: Oct 6, 2026, 10:09 AM EDT
EYPT
EyePoint Pharmaceuticals, Inc.
$3.11HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
Total return — ANIK vs EYPT
growth of $100 · dividends reinvested · last 10yANIK -57.8% (-8.3%/yr)EYPT -86.8% (-18.3%/yr)ANIK compounded faster over this window
ANIK EYPT
ANIK vs EYPT: by the numbers
- •ANIK is the larger company ($262M vs $261M market cap).
- •Both run net losses; ANIK's is the smaller (-3.14% vs -10994.73% net margin).
- •Both shrank revenue over the past five years; ANIK's decline was smaller (-2.48% vs -41.05% CAGR).
Metrics side by side
Valuation
| Metric | ANIK | EYPT |
|---|---|---|
| Forward P/E | 18.64 | N/A |
| P/S ratio | 2.17 | 93.49 |
| P/B ratio | 1.91 | 1.57 |
| EV / EBITDA | 484.89 | N/A |
| FCF yield | 0.21% | N/A |
Profitability
| Metric | ANIK | EYPT |
|---|---|---|
| Gross margin | 62.16% | 93.41% |
| Operating margin | -4.24% | -775.98% |
| Net margin | -3.14% | -10994.73% |
| ROE | -2.76% | -184.27% |
| ROIC | -3.17% | -170.19% |
Growth (annualized)
| Metric | ANIK | EYPT |
|---|---|---|
| Revenue CAGR (5Y) | -2.48% | -41.05% |
| FCF CAGR (5Y) | -39.38% | N/A |
| Total return CAGR (5Y) | -13.40% | -21.68% |
Frequently asked
- Which has grown faster, ANIK or EYPT?
- Neither grew: over the past five years both shrank revenue, with ANIK's decline the smaller — ANIK at a -2.48% CAGR versus EYPT at -41.05%.
- How have ANIK and EYPT total returns compared?
- Over the past 10 years, ANIK delivered -8.51% and EYPT delivered -20.02% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.